MLKL is a key factor in necroptosis execution,574,576,590 and a vital determinant of treatment response and poor prognosis in cancer patients.579,591 The low expression level of MLKL is significantly associated with lower OS in gastric cancer,592 ovarian cancer,593 cervical SCC,594 colon cancer,577,595 and pancreatic cancer.591 Moreover, in resected PADC patients receiving adjuvant chemotherapy, the low expression level of MLKL is related to decreased RFS. Here, MLKL is linked to familial pancreatic carcinoma.